China Life Science and Biotech Development Report 2021 Released in Chengdu

On October 20th, 2021 China Biotech Innovation Conference, a national grand event in biotechnology, was officially opened in Chengdu, Sichuan. Nearly 30 academicians, over 300 leading experts, 1,000 scholars, and representatives of about 20 Fortune 500 multinational pharmaceutical companies and more than 50 well-known domestic and foreign pharmaceutical enterprises gathered in Chengdu to discuss the new development of biotechnology in China.

Explore the new landscape for biomedicine

Academician WEI Yuquan released an authoritative report

With the theme of "Self-reliance in Science and Technology to Promote People's Health", this conference depicts the general picture of biotech development in China during the 13th Five-Year Plan, envisions the pathway of biotech development for the 14th Five-Year Plan, and explores the prospect of innovation in biomedicine. 

At the opening ceremony, three academicians, ZHANG Boli, WEI Yuquan and LU Lin, released long-expected reports on medicine and biotechnology which received particular attention and prolonged applause. 

Among them, Professor WEI Yuquan, Academician of Chinese Academy of Sciences and Founder of Chengdu WestVac BioPharma Co., Ltd., on behalf of China National Center for Biotechnology Development of the Ministry of Science and Technology, launched China Life Science and Biotech Development Report 2021, which updates the advanced progress in life science in 2020 focusing on the emerging hot spots in biotechnology, and analyzes the industrial trend, showing that life science and biotechnology in China are moving towards a new stage featuring systematic, digital and engineering-based development. 

Promote high-quality biomedicine development 

WestVac expedites technological innovation 

Leading biopharma enterprises in Chengdu also made presence on the conference, such as WestVac Biopharma Co., Ltd. based in Tianfu International Bio-town in the High-Tech Industrial Development Zone. As a newly listed unicorn company in 2021, WestVac Biopharma is dedicated to the research, development and commercialization of vaccines and immunotherapies. 

According to Professor WEI Yuquan, Academician of Chinese Academy of Sciences and Chairman of WestVac, since the onset of COVID-19 outbreak, Chengdu High-Tech Industrial Development Zone has been paying close attention to the vaccine development, and making arrangements for product commercialization and business incubation in advance, greatly facilitating the R&D progress in WestVac Biopharma. Furthermore, Chengdu High-Tech Industrial Development Zone has coordinated all efforts to support WestVac from early phase investment, facility construction to financing recommendation, contributing to its leap-forward development with a leverage of nearly 200 times.